Clinical Trial Update: Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the efficacy and safety of a Grazoprevir/Elbasvir plus Ribavirin regimen in genotype 2 Hepatitis C infection; completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Elbasvir (elbasvir)
• Grazoprevir (grazoprevir)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2016-03-04